Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
Portfolio Companies: RA Capital Management
Kala Pharmaceuticals, Inc. (NASDAQ: KALA)

Organization & Developments: Kala

Parents

2014: Kala Pharmaceuticals ready to begin several trials for eye diseases (2014)
2017: US Biotech/Pharma Sector Update: July 20: Featuring Kala Pharma, IPO (Upcoming Catalyst) - Bhavneesh Sharma, MBA
2018: Kala Pharmaceuticals: Update And 2019 Outlook_seekingalpha.com
2020: Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
2020: Kala Pharmaceuticals: A Post Q1 Assessment
2020: Revisiting Kala Pharmaceuticals_seekingalpha.com
2020: The Play On Kala Pharmaceuticals
2020: Two Recent Positives For Kala Pharmaceuticals
2021: Kala Pharmaceuticals: Eye Treatment Specialist With Much To Prove May Have Just The Product
Dry eye disease: - MPP technology may help to give temporary relief from sign and symptoms of this disease.
Founded upon a proprietary drug delivery technology
Mucus Penetrating Particles or MPPs are selectively sized nanoparticles with proprietary non-covalent coatings.
Ocular surgery: - This technology may help in the treatment of post operative inflammation and pain gain from this surgery. This is a common type of surgery in US.